Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

69.05USD
21 Sep 2018
Change (% chg)

$0.26 (+0.38%)
Prev Close
$68.79
Open
$68.96
Day's High
$69.25
Day's Low
$68.88
Volume
5,370,420
Avg. Vol
1,481,586
52-wk High
$69.25
52-wk Low
$51.38

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

Financials

  ABT.N Industry Sector
P/E (TTM): 84.45 30.93 32.76
EPS (TTM): 0.65 -- --
ROI: 2.24 15.07 14.61
ROE: 4.07 16.59 16.33

Abbott Labs raises 2018 earnings forecast, shares hit record high

Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.

18 Jul 2018

UPDATE 2-Abbott Labs raises 2018 earnings forecast, shares hit record high

* Shares hit record high (Adds details from conference call, analysts' quotes, updates shares)

18 Jul 2018

Abbott Labs tops profit estimates, raises full-year earnings forecast

July 18 Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses, including its top-earning medical device unit.

18 Jul 2018

Allergan appoints former Abbott executive to its board

Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

14 Jun 2018

Allergan appoints former Abbott executive to its board

June 14 Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

14 Jun 2018

BRIEF-Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER

03 May 2018

Outgoing Smith & Nephew CEO signs off with a downgrade

LONDON Smith & Nephew downgraded its revenue and profit forecasts after a weak first quarter on Thursday, days before Chief Executive Olivier Bohuon will end his seven-year tenure at the artificial knee and hip maker.

03 May 2018

UPDATE 2-Outgoing Smith & Nephew CEO signs off with a downgrade

* Shares fall 7 pct (Adds CEO comments, analyst reaction, shares)

03 May 2018

BRIEF-Abbott's Xience Sierra Heart Stent Receives National Reimbursement In Japan

* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-Abbott Laboratories Says Shareholders Rejected Proposal Requesting Board Of Directors Adopt Policy That Board Chairman Be Independent Director

* ABBOTT LABORATORIES SAYS SHAREHOLDERS REJECTED PROPOSAL REQUESTING CO'S BOARD OF DIRECTORS ADOPT POLICY THAT BOARD CHAIRMAN BE INDEPENDENT DIRECTOR Source text: (https://bit.ly/2KqCwQY) Further company coverage:

30 Apr 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.88 +0.90
Pfizer Inc. (PFE.N) $44.06 +0.31
Novartis AG (NOVN.S) CHF81.88 -0.06
Merck & Co., Inc. (MRK.N) $71.10 +0.32
Sanofi SA (SASY.PA) €74.50 -0.17
AstraZeneca plc (AZN.L) 5,670.00 +98.00
GlaxoSmithKline plc (GSK.L) 1,531.40 +45.60
Eli Lilly And Co (LLY.N) $106.33 +0.26
Amgen, Inc. (AMGN.OQ) $205.10 0.00
Boston Scientific Corporation (BSX.N) $37.77 -0.05

Earnings vs. Estimates